Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Detour on the Road to a Cure

被引：2
|
作者：
Sledge, George W., Jr. [1 ]
机构：
[1] Stanford Univ, Sch Med, Stanford, CA 94305 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 10期
关键词：
TRASTUZUMAB; LAPATINIB; PERTUZUMAB; EFFICACY; SAFETY;
D O I：
10.1200/JCO.2015.64.7511
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1021 / +
页数：4
相关论文
共 50 条
  • [1] Tailored duration of adjuvant trastuzumab for human epidermal growth factor receptor 2-positive breast cancer
    Ke-Da Yu
    Xin Wang
    Wan-Kun Chen
    Lei Fan
    Miao Mo
    Han Chen
    npj Precision Oncology, 4
  • [2] Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer
    Liberato, Nicola Lucio
    Marchetti, Monia
    Barosi, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (06) : 625 - 633
  • [3] Tailored duration of adjuvant trastuzumab for human epidermal growth factor receptor 2-positive breast cancer
    Yu, Ke-Da
    Wang, Xin
    Chen, Wan-Kun
    Fan, Lei
    Mo, Miao
    Chen, Han
    NPJ PRECISION ONCOLOGY, 2020, 4 (01)
  • [4] Implications of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
    Wolff, Antonio C.
    Tung, Nadine M.
    Carey, Lisa A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (25) : 2189 - +
  • [5] Antibody-Drug Conjugates as an Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer
    Asazuma, Kazuki
    Shimomura, Akihiko
    Shimizu, Chikako
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (18) : 2066 - +
  • [6] Ongoing Debate: Anthracyclines and Adjuvant Treatment of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
    Mahesh, Sameer
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (35) : 4445 - 4446
  • [7] Tailored duration of adjuvant trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer
    Yu, Ke-Da
    Zhou, Zhi-Rui
    Shao, Zhi-Ming
    CANCER RESEARCH, 2020, 80 (04)
  • [8] Short-course adjuvant trastuzumab will increase cure rates in patients with human epidermal growth factor receptor 2-positive breast cancer
    Abratt, Raymond P.
    SAMJ SOUTH AFRICAN MEDICAL JOURNAL, 2017, 107 (08): : 654 - 655
  • [9] Trastuzumab: A Milestone in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
    Dhanushkodi, Manikandan
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2020, 41 (01) : 54 - 56
  • [10] Therapeutic Landscape of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
    Xie, Jindong
    Zou, Yutian
    Gao, Ting
    Xie, Liming
    Tan, Duxun
    Xie, Xiaoming
    CANCER CONTROL, 2022, 29
12345